KISIMA-01 Investigates the Safety of ATP128 With or Without Ezabenlimab in CRC
August 12th 2021Scott Kopetz, MD, PhD, FACP, explains the purpose of the phase 1b KISIMA-01 study of the ATP128 vaccine used with or without with or without ezabenlimab to treat patients with advanced colorectal cancer.
Watch
Tucatinib, Trastuzumab, and Capecitabine Improve OS, PFS in HER+ Breast Cancer
August 9th 2021Guiseppe Curigliano, MD, discusses the design and results of the HER2CLIMB-02 study which evaluated the efficacy of tucatinib in combination with trastuzumab and capecitabine in HER2-positive breast cancer patients with and without brain metastases compared to placebo.
Watch
Maintenance Vigil I/O Shows Efficacy in HRD-Proficient Advanced Ovarian Cancer
August 6th 2021Rodney P. Rocconi, MD, discusses a subgroup analysis of the phase 2b VITAL study in which the efficacy of maintenance Vigil immunotherapy is explored in patients with newly diagnose advanced ovarian cancer who are homologous recombination proficient.
Watch
Accuracy of PREDICT+ to Determine OS in Early Breast Cancer
July 31st 2021Elisa Agostinetto, MD, discusses the accuracy of PREDICT+, an online tool used to predict mortality in patients with early breast cancer patients and to aid in clinical decision making, to determine the survival of patients enrolled in the phase 3 ALTTO trial of adjuvant lapatinib with or without trastuzumab versus trastuzumab alone in patients with HER2+ early breast cancer.
Watch
Transplant Eligible Patients With DLBCL
July 30th 2021Loretta Nastoupil, MD, and John Burke, MD, discuss transplant as a treatment option for patients with relapsed/refractory [R/R] diffuse large B-cell lymphoma [DLBCL], as well as treatment options for patients with relapsed disease after transplant.
Watch